Myriad Genetics (MYGN) Operating Expenses (2009 - 2026)

Myriad Genetics (MYGN) has reported Operating Expenses for 18 consecutive years, with $168.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 3.12% year-over-year to $168.3 million; the TTM figure through Mar 2026 stood at $968.9 million (up 37.14% YoY), while the FY2025 annual figure was $963.8 million, up 35.96% from the prior year.
• Operating Expenses climbed to $168.3 million in Q1 2026 per MYGN's latest filing, from $152.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $481.0 million in Q2 2025 and bottomed at -$8.2 million in Q4 2023.
• Historically, Operating Expenses has averaged $190.1 million across 5 years, with a median of $183.6 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Expenses sank 129.29% — and 2024, when it soared 2415.85%.
• Myriad Genetics' Operating Expenses stood at $28.0 million in 2022, then slumped by 129.29% to -$8.2 million in 2023, then jumped by 2415.85% to $189.9 million in 2024, then slipped by 19.69% to $152.5 million in 2025, then grew by 10.36% to $168.3 million in 2026.
• Business Quant data shows MYGN's Operating Expenses at $168.3 million in Q1 2026, $152.5 million in Q4 2025, and $167.1 million in Q3 2025.